Compare NPK & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | CMPX |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.1M | 927.5M |
| IPO Year | 1994 | 2020 |
| Metric | NPK | CMPX |
|---|---|---|
| Price | $135.05 | $5.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.43 |
| AVG Volume (30 Days) | 79.3K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $677.91 |
| P/E Ratio | $141.42 | ★ N/A |
| Revenue Growth | ★ 29.70 | N/A |
| 52 Week Low | $77.63 | $1.52 |
| 52 Week High | $149.86 | $6.88 |
| Indicator | NPK | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 45.77 |
| Support Level | $128.22 | $4.86 |
| Resistance Level | $137.78 | $5.77 |
| Average True Range (ATR) | 5.24 | 0.29 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 50.38 | 51.74 |
National Presto Industries Inc has an eclectic product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments namely Defense, Housewares/Small Appliance, and Safety. The defense segment which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases; performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances; the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.